Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Narendra BharathyNoah E BerlowEric WangJinu AbrahamTeagan P SettelmeyerJody E HooperMatthew N SvalinaZia BajwaMartin W GorosBrian S HernandezJohannes E WolffRanadip PalAngela M DaviesArya AshokDarnell BushbyMaria ManciniChristopher NoakesNeal C GoodwinPeter OrdentlichJames KeckDouglas S HawkinsErin R RudzinskiAtiya MansoorTheodore J PerkinsChristopher R VakocJoel E MichalekCharles KellerPublished in: Skeletal muscle (2019)
Our results suggest that the targeting class I HDACs may provide a therapeutic benefit for selected patients with eRMS. ENT's preclinical in vivo efficacy makes ENT a rational drug candidate in a phase II clinical trial for eRMS.